Mitochondrial signalling peptides and targeted compounds with real scientific interest but very different stages of clinical development.
A strong mechanistic story around AMPK, insulin sensitivity, mitochondrial function and age-related decline.
MOTS-c entered a phase 2a metabolic trial in 2026; this is not evidence of efficacy. Elamipretide is being studied for defined mitochondrial diseases.
Track as translational research, not a self-experimentation category.